Resolve™ – Revolutionary fractional module for PicoWay with 2 wavelengths: 532nm and 1064nm for skin rejuvenation, pigmented lesions and toning
WAYLAND, Massachusetts, Oct. 8, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today the international launch of PicoWay Resolve™, the revolutionary dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve fractional picosecond modality, which features both 532nm and 1064nm wavelengths, comes less than a year after the November 2014 launch of the state-of-the-art PicoWay platform.
Video - https://youtu.be/vpUud9UnuKk
Photo - http://photos.prnewswire.com/prnh/20151008/275308
Photo - http://photos.prnewswire.com/prnh/20151008/275309
Logo - http://photos.prnewswire.com/prnh/20120528/535447
PicoWay utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. PicoWay delivers the shortest picosecond pulses and the highest peak power of any picosecond device on the market.
Resolve is the only picosecond device on the market to employ a holographic fractionator to deliver precisely consistent energy to the entire treatment area, which results in pristine, reproducible results. Resolve's two wavelengths enable treatment of shallow lesions with the 532nm wavelength, while the 1064nm wavelength is used for deeper lesions and to treat all skin types, with no downtime.
"PicoWay continues to exceed expectations and delight customers. We are thrilled to introduce to the market the next step in the PicoWay story, Resolve, the fractional modality that uniquely includes two wavelengths. Our PicoWay customers know that we have a robust road map for PicoWay which includes expanded applications and new capabilities enabled by outstanding technology," said Amit Meridor, Chief Executive Officer of Syneron Candela. "It is energizing to witness the excitement that this product is experiencing in the marketplace as we introduce appealing new ways to utilize the technology to treat patients."
"We recently began to use the novel PicoWay fractional handpieces for skin rejuvenation, acne scars and wrinkles with improvement in skin tone, brightness and texture after one or two treatments," said David Friedman, MD, board certified dermatologist.
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Syneron Medical – Public Relations
Hugo Goldman, Chief Financial Officer
+ 972 73 244 2283
Zack Kubow, The Ruth Group